News & Updates
Showing Dermatology articles
Showing
Show Multimedia Only

Long-term denifanstat sustains efficacy, safety for moderate-to-severe acne vulgaris
17 Oct 2026
byStephen Padilla
Long-term use of the fatty acid synthase (FASN) inhibitor denifanstat maintains its clinical efficacy in patients with moderate-to-severe acne without compromising their safety, according to a phase III extension study (ASC40-304) presented at EADV 2026.
17 Oct 2026







